CollPlant Biotechnologies Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K filing covers the month of January 2023 for CollPlant Biotechnologies Ltd., a foreign private issuer based in Rehovot, Israel. The report discloses a corporate press release issued on January 3, 2023, regarding a new product launch.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a disclosure of a corporate event rather than a financial statement.
Material Changes
The primary material change disclosed is the expansion of the company's portfolio of rhCollagen-based bioinks with the launch of Collink.3D™ 50L in powder form.
Guidance, Outlook, and Risks
The filing does not contain specific financial guidance, management commentary on future performance, or a discussion of risks and contingencies beyond the context of the product launch.
Key Facts for Investor Verification
- CollPlant Biotechnologies Ltd. launched Collink.3D™ 50L in powder form on January 3, 2023.
- The new product is an addition to the company's rhCollagen-based bioinks portfolio.
- The report was signed by Eran Rotem, Deputy CEO and Chief Financial Officer.
- No financial performance data is included in this specific filing.